Transform Wealth LLC Has $10.03 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Transform Wealth LLC lifted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 3.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,900 shares of the pharmaceutical company's stock after purchasing an additional 891 shares during the quarter. Transform Wealth LLC's holdings in Vertex Pharmaceuticals were worth $10,027,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of VRTX. Pacer Advisors Inc. raised its holdings in shares of Vertex Pharmaceuticals by 2.9% during the second quarter. Pacer Advisors Inc. now owns 38,326 shares of the pharmaceutical company's stock worth $17,964,000 after acquiring an additional 1,085 shares during the period. Thrivent Financial for Lutherans raised its stake in shares of Vertex Pharmaceuticals by 6.5% in the 2nd quarter. Thrivent Financial for Lutherans now owns 94,794 shares of the pharmaceutical company's stock valued at $44,432,000 after purchasing an additional 5,827 shares during the period. Itau Unibanco Holding S.A. acquired a new position in shares of Vertex Pharmaceuticals during the second quarter worth about $77,000. EverSource Wealth Advisors LLC grew its holdings in shares of Vertex Pharmaceuticals by 5.8% during the second quarter. EverSource Wealth Advisors LLC now owns 598 shares of the pharmaceutical company's stock worth $296,000 after buying an additional 33 shares in the last quarter. Finally, Cyrus J. Lawrence LLC raised its position in Vertex Pharmaceuticals by 93.1% in the 2nd quarter. Cyrus J. Lawrence LLC now owns 26,488 shares of the pharmaceutical company's stock valued at $12,415,000 after buying an additional 12,769 shares during the last quarter. Institutional investors own 90.96% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Oppenheimer cut shares of Vertex Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Thursday, December 19th. Jefferies Financial Group upgraded shares of Vertex Pharmaceuticals from a "hold" rating to a "buy" rating and lifted their price target for the company from $500.00 to $550.00 in a research note on Monday, December 9th. William Blair reaffirmed an "outperform" rating on shares of Vertex Pharmaceuticals in a research report on Monday, January 13th. JPMorgan Chase & Co. reduced their price target on Vertex Pharmaceuticals from $503.00 to $500.00 and set an "overweight" rating for the company in a research report on Monday, December 23rd. Finally, Raymond James reaffirmed a "market perform" rating on shares of Vertex Pharmaceuticals in a research report on Thursday, October 10th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $490.38.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX traded up $6.47 during trading on Tuesday, reaching $428.47. The company's stock had a trading volume of 832,211 shares, compared to its average volume of 1,486,234. The firm has a 50 day moving average price of $439.34 and a 200 day moving average price of $465.72. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The firm has a market capitalization of $110.34 billion, a price-to-earnings ratio of -215.28, a price-to-earnings-growth ratio of 2.17 and a beta of 0.40. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.61 by $0.77. The business had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The firm's quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.67 earnings per share. As a group, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.